Abstracts tagged "Cardiovascular"

Abstract Number: 1089 • ACR Convergence 2024
Endothelial Activation in Gout
Michael Toprover¹, Binita Shah², Kamelia Drenkova², Michael Pillinger³ and Michael Garshick⁴, ¹New York University Langone Health, New York, NY, ²NYU Langone Health, New York, NY, ³New York University Grossman School of Medicine, New York,, NY, ⁴NYU Langone Health, Tenafly, NJ
Background/Purpose: Gout is the most common inflammatory arthritis and is associated with increased cardiovascular (CV) disease and cardiovascular mortality. Our prior studies have suggested that…
Abstract Number: 1484 • ACR Convergence 2024
A Retrospective Evaluation of Glucagon-like Peptide-1 Receptor Agonists in SLE Patients
Philip Carlucci¹, Brooke Cohen², Amit Saxena³, H Michael Belmont³, Mala Masson⁴, Heather Gold⁵, Jill Buyon² and Peter Izmirly⁶, ¹New York University School of Medicine, New York, NY, ²NYU Grossman School of Medicine, New York, NY, ³NYU School of Medicine, New York, NY, ⁴NYU Langone Health, New York, NY, ⁵NYU Langone Health, NYC, ⁶New York University Grossman School of Medicine, New York, NY
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP1-RA) are an emerging class of medications that significantly improve cardiometabolic outcomes. Whether these drugs may be useful in mitigating…
Abstract Number: 1898 • ACR Convergence 2024
Hyperuricemia Is Associated with Higher Levels of Fasting Plasma Glucose and Insulin Resistance in Non-diabetic Subjects
Janis Timsans¹, Jenni Kauppi¹, Anne Kerola², Vappu Rantalaiho³, Hannu Kautiainen⁴ and Markku Kauppi², ¹Päijät-Häme Central Hospital, Lahti, Finland, ²Päijät-Häme Central Hospital, University of Helsinki, Lahti, Finland, ³Tampere University Hospital, Tampere University and Kanta-Häme Central Hospital, Tampere, Finland, ⁴Folkhälsan Research Center, Helsinki, Finland
Background/Purpose: Disorders of glucose metabolism are well-known major contributors to morbidity and mortality. Elevated serum uric acid (SUA), a key precursor of gout attacks, is…
Abstract Number: 2275 • ACR Convergence 2024
Cardiovascular and Cancer Safety of JAKi Compared to TNFi in Patients with Rheumatoid Arthritis: Results from a National Registry of Advanced Therapies
Lucia Otero-Varela¹, Carlos Sanchez-Piedra², Elena Rabadán Rubio³, Juan Camilo Sarmiento-Monroy⁴, Chamaida Plasencia-Rodríguez⁵, Diana Sueiro⁶, Olga Martinez⁷, Noemí Busquets Pérez⁸, Mercedes Freire González⁹, Fernando Sánchez-Alonso¹⁰, José María Álvaro-Gracia¹¹ and Isabel Castrejon¹², and BIOBADASER group, ¹Spanish Society of Rheumatology, Madrid, Spain, ²Agencia de Evaluación de Tecnologías Sanitarias, Instituto de Salud Carlos III, Madrid, Spain, ³Hospital Universitario Principe de Asturias, Alcalá de Henares, Madrid, Spain, ⁴Hospital Clínic Barcelona, Barcelona, Spain, ⁵Hospital Universitario La Paz, MADRID, Spain, ⁶Complexo Hospitalario Universitario de Ourense, Ourense, Spain, ⁷Hospital Universitario de Salamanca, Zamora, Spain, ⁸HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, ⁹Complexo Hospitalario Universitario de A Coruña, La coruna, Galicia, Spain, ¹⁰Sociedad Española de Reumatología, Madrid, Spain, ¹¹Hospital Gregorio Marañón, Madrid, Spain, ¹²Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Preliminary results from the ORAL Surveillance clinical trial showed an increase in the risk of major adverse cardiovascular events (MACE) and malignancies in patients…
Abstract Number: 0069 • ACR Convergence 2024
Activation of Cardiovascular Inflammation and Wnt Signaling in Spondyloarthritis: Insights from the HLA-B27 Transgenic Rat Model
Su-Ah Yoon, Chorong Kim, Hansun Song, Mie Jin Lim and Seong-Ryul Kwon, College of Medicine, Inha University, Incheon, Republic of Korea
Background/Purpose: Despite the well-documented link between cardiovascular (CV) disease and spondyloarthritis (SpA), no animal studies have empirically validated this connection or integrated SpA, vascular inflammation,…
Abstract Number: 0463 • ACR Convergence 2024
Evaluation of Inflammatory Indices as Predictive Biomarkers of Carotid Plaque in Patients with Rheumatoid Arthritis
Jose Antonio Davila Jimenez¹, Dionicio Galarza-Delgado², Iris Jazmín Colunga Pedraza³, jose Ramon Azpiri-Lopez⁴, Rosa Icela Arvizu-Rivera³, Jesus Cardenas-de la Garza⁵, Aleydis Gonzalez Melendez³, Andrea Guajardo Aldaco³, Maria F. Elizondo-Benitez⁶, Rebeca L. Polina-Lugo³ and Diego Salcedo-Almanza⁷, ¹Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁵Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ⁶Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁷Division of Radiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased cardiovascular (CV) risk compared to the general population. All stages of the atherogenic process appear to…
Abstract Number: 0705 • ACR Convergence 2024
Identification of Risk Factors for Incident Cardiomyopathy in Patients with Systemic Sclerosis
Ji Soo Kim¹, Rachel Wallwork¹, Carrie Richardson², Adrianne Woods³, Monica Mukherjee⁴, Steven Hsu⁴, Julie Paik¹, Christopher Mecoli¹, Laura Hummers⁵, Fredrick Wigley⁶, Scott Zeger¹ and Ami Shah⁷, ¹Johns Hopkins University, Baltimore, MD, ²Northwestern University, Chicago, ³Johns Hopkins University Division of Rheumatology, Baltimore, MD, ⁴Johns Hopkins University Division of Cardiology, Baltimore, MD, ⁵Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁶Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, ⁷Division of Rheumatology, Johns Hopkins University, Ellicott City, MD
Background/Purpose: Cardiac involvement in systemic sclerosis (SSc) is one of the leading causes of scleroderma-associated death. There are limited data examining risk factors for incident…
Abstract Number: 1097 • ACR Convergence 2024
CERT Score as a Potential Tool to Predict Cardiovascular Risk in Gout and Hyperuricemia
Blanka Stiburkova¹, Aleš Kvasnička², Barbora Pisklakova², Jakub Rozhon², Karel Pavelka³ and David Friedecky², ¹Institute of Rheumatology, Prague, Czech Republic and Department of Paediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic, Prague, Czech Republic, ²Laboratory for Inherited Metabolic Disorders, Department of Clinical Biochemistry, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic, Olomouc, Czech Republic, ³Institute of Rheumatology and Charles University, Praha, Czech Republic
Background/Purpose: Asymptomatic hyperuricemia and gout are two clinical conditions associated with a high risk of cardiovascular events and mortality. Recent data suggest that the number…
Abstract Number: 1486 • ACR Convergence 2024
Cardiovascular Risk in Systemic Lupus Erythematosus: Carotid Ultrasonography Is Useful for the Re-stratification of Cardiovascular Risk Determined by Score2
Cristina Corrales Selaya¹, Carmen Bejerano², Carmen Secada Gómez³, Virginia Portilla-González⁴, Ricardo Blanco-Alonso⁵, Victor Manuel Martinez Taboada⁶, Leyre Riancho⁷ and alfonso Corrales-Martínez⁸, ¹Rheumatology, Marques de Valdecilla University Hospital. IDIVAL, Santander, Cantabria, Spain, ²Hospital Universitario Marques de Valdecilla, Immunopathology group, IDIVAL, Santander, Cantabria, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ⁶Facultad de Medicina. Universidad de Cantabria, Santander, Cantabria, Spain, ⁷Hospital Sierrallana, Torrelavega, Cantabria, Spain, ⁸Hospital Universitario Marques de Valdecilla, Santander, Spain

Background/Purpose: Systemic lupus erythematosus (SLE) patients have an increased cardiovascular (CV) risk compared to the general population. Although SCORE2 (systematic coronary risk evaluation 2) has…
Abstract Number: 1899 • ACR Convergence 2024
Recurrent Heart Failure Hospitalization in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study
Tate Johnson¹, Yangyuna Yang¹, Punyasha Roul², Joshua Baker³, Gary Kunkel⁴, Sauer brian⁵, grant Cannon⁶, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: People with rheumatoid arthritis (RA) are at an increased risk of heart failure (HF), which is among the most burdensome chronic conditions and a…
Abstract Number: 2357 • ACR Convergence 2024
Longitudinal Evaluation of Neutrophil-to-Lymphocyte Ratio in Guselkumab-Treated Patients with Psoriatic Disease and Levels of Systemic Inflammation Associated with Elevated Cardiovascular Risk: Post-hoc Analysis of 4 Phase 3, Randomized, Controlled Studies
Joseph Merola¹, Alexis Ogdie², Arthur Kavanaugh³, Evan Leibowitz⁴, Emmanouil Rampakakis⁵, Ryan Funk⁶, Francois Nantel⁷, Frederic Lavie⁸, Katelyn Rowland⁹ and Enrique R. Soriano¹⁰, ¹UT Southwestern Medical Center, Newton, MA, ²Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³University of California San Diego, La Jolla, CA, ⁴Janssen Scientific Affairs, LLC, Fair Lawn, NJ, ⁵McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ⁶Johnson & Johnson Innovative Medicine, Long Grove, IL, ⁷Nantel MedSci Consult, Montreal, QC, Canada, ⁸Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ⁹Janssen Pharmaceuticals, Horsham, PA, ¹⁰Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Psoriatic disease (PsD) is associated with an increased risk of cardiovascular (CV) disease. Neutrophil-to-lymphocyte ratio (NLR) is a biomarker of systemic inflammation; NLR ≥2.5…
Abstract Number: 0098 • ACR Convergence 2024
Anti-HSP90α as a Protective Natural Antibody Against Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus
Marina Barguil Macedo¹, Jorge Armando Gonzalez-Chapa¹, Anders Bengtsson², Iva Gunnarsson³, Elisabet Svenungsson⁴ and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Lund University, Lund, Sweden, ³Karolinska Institute, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Heat shock protein 90 alpha (HSP90α) is an epichaperone present ubiquitously inside the cell, whose dimers function as a foldase that helps the correct…
Abstract Number: 0469 • ACR Convergence 2024
SCORE2 Is Superior to SCORE in Predicting the Presence of Carotid Plaques and Intima-media Thickness in Rheumatoid Arthritis Patients: A Cross-sectional Study with Carotid Ultrasound
Cristina Campos Fernández¹, Jorge Juan Fragío Gil², Roxana González Mazario³, Pablo Martínez Calabuig⁴, Laura Salvador Maicas⁵, Mireia Lucía Sanmartín Martínez⁶, Iván Jesús Lorente Betanzos⁶, Clara Molina Almela⁶, juan José Lerma Garrido⁷, Amalia Rueda³ and Jose A Román-Ivorra⁸, ¹Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain, ²Hospital General Universitario, Valencia, Comunidad Valenciana, Spain, ³Hospital General de Valencia, Valencia, Comunidad Valenciana, Spain, ⁴HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, ⁵Consorcio Hospital General Universitario de Valencia, Castellón de la Plana, Comunidad Valenciana, Spain, ⁶Consorcio Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, ⁷Hospital General Universitario Valencia, Valencia, Comunidad Valenciana, Spain, ⁸Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Rheumatoid arthritis (RA) escalates the risk of premature mortality, predominantly through cardiovascular diseases. Although SCORE and its updated version, SCORE2, are employed to assess…
Abstract Number: 0735 • ACR Convergence 2024
ANCA-associated Vasculitis (AAV) and Long-term Risk of Cardiovascular Disease: Large-scale Propensity-matched Global Retrospective Cohort Study
Sebastian Klapa¹, Henry Nording², Marlene Ludwig³, Sabrina Arnold⁴, Khalaf Kridin⁵, Anja Staehle⁶, Ralf Ludwig⁷ and Peter Lamprecht⁴, ¹University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, ²University of Lübeck, Cardioimmunology Research Group, Lübeck, Germany, ³Independent Researcher, Groß Grönau, Germany, ⁴University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, ⁵5. Bar-Ilan University, Azrieli Faculty of Medicine, Safed, Israel, ⁶University of Lübeck, Department of Rheumatology and Immunology, Lübeck, Germany, ⁷University of Lübeck, Lübeck Institute of Experimental Dermatology, Lübeck, Germany
Background/Purpose: In spite of significantly improved therapy during the last years, long-term morbidity and mortality has remained high in ANCA-associated vasculitis (AAV). The main causes…
Abstract Number: 1098 • ACR Convergence 2024
Prognostic Value of Hyperuricemia in Developing Cardiovascular Events in Patients with Chronic Inflammatory Arthritis: A 10-Year Prospective Study
Antonio Avilés¹, Zulema Plaza², Fernando Sánchez-Alonso³, Santos Castañeda⁴, Benjamin fernandez-Gutierrez⁵, César Díaz⁶, Pilar Font⁷, Olga Martinez⁸, Emilio Giner⁹, José Miguel Senabre¹⁰, Amalia Rueda¹¹, Ana Perez¹², Gines Sanchez¹³, Carlos Gonzalez¹⁴, Javier García¹⁵, Javier Llorca¹⁶, Miguel Angel Gonzalez-Gay¹⁷ and Mariano Andres¹⁸, and CARMA project, reserch group., ¹Rheumatology section, Dr. Balmis General University Hospital-ISABIAL, Alicante, Spain, Alicante, Spain, ²Fundacion Española de Reumatología, Madrid, Spain, ³Sociedad Española de Reumatología, Madrid, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵HOSPITAL CLINICO SAN CARLOS, Madrid, Spain, ⁶Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁷IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁸Hospital Universitario de Salamanca, Zamora, Spain, ⁹Hospital Royo Villanova, Teruel, Spain, ¹⁰Hospital Marina Baixa Alicante, Alicante, Spain, ¹¹Hospital General de Valencia, VALENCIA, Comunidad Valenciana, Spain, ¹²Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain, ¹³Hospital General de Albacete, Albacete, Spain, ¹⁴Hospital Universitario Lucus Augusti; Biodiscovery HULA-USC Group, Instituto de Investigación Sanitaria de Santiago de Compostela IDIS., Lugo, Spain, ¹⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁶CIBER Epidemiología y Salud Pública (CIBERESP) and Department of Medical and Surgical Sciences, University of Cantabria, Santander, Spain, ¹⁷University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ¹⁸Hospital General Universitario de Alicante, Alicante, Spain
Background/Purpose: The role of concurrent hyperuricemia as a cardiovascular risk factor in patients with chronic inflammatory arthritis (CIA) has yet to be studied. We aim…

« Previous Page
1
…
4
5
6
7
8
…
31
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].